A new study published in Frontiers in Pediatrics reports that cannabidiol (CBD) may significantly strengthen the seizure-reducing effects of phenobarbital (PB) in newborns, particularly when PB is given at doses too low to work on its own.
The research team from the Federal University of Alagoas and the Federal University of Minas Gerais used a neonatal rat model to test how CBD and PB interact during chemically induced seizures. Ten-day-old Wistar rats were pretreated with various doses of CBD or PB before being exposed to pentylenetetrazole, a compound used to trigger seizures for experimental purposes. The study then measured seizure latency, duration, and severity.
CBD alone provided only modest seizure protection at higher doses, while low doses offered little benefit. PB showed similar limitations at the lowest levels tested. But when CBD was paired with a low, otherwise ineffective PB dose of 10 mg/kg, the combination produced a clear and dose-dependent improvement in seizure control. CBD at 30, 100, and 200 mg/kg notably enhanced PB’s ability to delay and reduce seizure activity.
According to the authors, the findings suggest that CBD could serve as a valuable add-on therapy for neonatal patients who do not respond well to PB alone. The study emphasizes the need for further research on dosing, safety, and potential clinical applications, given the limited treatment options for newborns with drug-resistant epilepsy.
The full text of the study can be found here.
More articles from The Marijuana Herald can be found below.
